Matthew L. Posard
CIK 1543792 · Chief Commercial Officer · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.10M
Companies
6
Total Filings
42
Lifetime Open-Market Net
-$5.17M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NAUT | Director | 130,000 | $1.20 | $156.0K | $225.5K | 6 | 2026-06-22 |
| HTI | Director | 77,835 | — | — | -$4.40M | 16 | 2026-05-07 |
| Talis Biomedical Corp (TLIS) Delisted | Director | 4,167 | $2.84 | $11.8K | $1.00M | 3 | 2023-06-12 |
| DermTech, Inc. (DMTK) Delisted | Director | 158,215 | $0.09 | $14.9K | $1000.0K | 8 | 2023-06-05 |
| Cardiff Oncology, Inc. (TROVW) Delisted | Chief Commercial Officer | — | — | — | $0 | 1 | 2016-01-06 |
| ILMN | Sr VP & General Manager | 30,858 | $192.59 | $5.94M | -$3.00M | 6 | 2013-05-30 |
Recent Filings · Page 2 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-16 | NAUT | Grant (A) | — | $0 | EDGAR |
| 2023-06-12 | Talis Biomedical Corp (TLIS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-05 | DermTech, Inc. (DMTK) Delisted | Grant (A) | +35,714 | $0 | EDGAR |
| 2023-05-09 | HTI | Grant (A) | +8,065 | $0 | EDGAR |
| 2022-12-06 | HTI | Sell (S) | −30,000 | -$1.71M | EDGAR |
| 2022-06-16 | NAUT | Grant (A) | — | $0 | EDGAR |
| 2022-06-13 | Talis Biomedical Corp (TLIS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-31 | DermTech, Inc. (DMTK) Delisted | Grant (A) | +26,480 | $0 | EDGAR |
| 2022-05-06 | HTI | Grant (A) | +6,206 | $0 | EDGAR |
| 2021-12-01 | NAUT | Buy (P) | +50,000 | $225.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.